Could pot be the anti-ageing regime you’ve been looking for?
Health & Biotech
Pot stock eSense Lab (ASX:ESE) says it has tested its medicinal cannabis strains and found “clear antioxidant activity”.
Antioxidants — usually found in “superfoods” such as goji berries, dark chocolate or kidney beans — are known for their ability to fight against the harmful oxidative effect of free radicals. Free radicals are unstable molecules that can lead to inflammatory diseases and ageing.
The British Medical Journal has previously reported “evidence is strong that regular, moderate use of cannabis helps to delay the onset and progression of Alzheimer’s disease and other neurodegenerative conditions”.
The US government even holds a patent — US6630507 Cannabinoids as antioxidants and neuroprotectants — that supports the role of cannabis “in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia”.
In a study of its own cannabis blends, eSense says it found its terpene strains Girl Scout Cookies, OG-Kush, Sour Diesel, Jack Herer and Daniel presented potent antioxidant activity.
Terpenes are fragrant plant oils that carry flavour and aroma. They carry the pungent odour of cannabis and offer some medicinal properties — but don’t contain THC, the compound that gets you stoned, or CBD which is the restricted bit used in medicinal products.
The shares increased 3 per cent on Friday morning to 18c.
“We are very excited about this progress. eSense continually achieves new R&D heights, providing an ability to significantly strengthen our IP as well as discovering new opportunities in revenue generating markets,” chief Haim Cohen said.
“Without doubt our team has shown its unique ability in the medical cannabis space and we’re continuing to take strides to becoming a leader in this market.”
Late last year it said it was making chocolate-flavoured terpenes.
While the scientists might be making strides in R&D, board shuffles have plagued the company’s management in the year so far.
After being postponed three times, its AGM has been scheduled for March 29 – at which shareholders will vote for blocks of leadership from the company or requisitioning shareholders made up of representatives from Romfal Sifat, Buzz Capital and Attollo Investment.
It’s a choice between current Israeli director Ilan Saad or Australian-based Brendan de Kauwe.
The move follows a spill movement in January by three Israeli shareholders to kick out Mr Saad, chief Haim Cohen and Eran Gilboa and a court case to get Mr deKauwe reinstated.